Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇ - Wikidata - wikimedia - TriplyDB

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

http://www.wikidata.org/entity/Q30040372

about

Biosynthesis of α-pyrones Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease Design and Synthesis of HIV-1 Protease Inhibitors Incorporating Oxazolidinones as P2/P2‘ Ligands in Pseudosymmetric Dipeptide Isosteres HIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant Variants Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance Structure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating Phenyloxazolidinones P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Novel compounds in preclinical/early clinical development for the treatment of HIV infections.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes Role of tipranavir in treatment of patients with multidrug-resistant HIV Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.Tipranavir: a new protease inhibitor for the pediatric population.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations.New anti-HIV agents and targets.Early factors in successful anti-HIV treatment.Molecular Basis for Drug Resistance in HIV-1 Protease Protocol for rational design of covalently interacting inhibitors.Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.Emerging anti-HIV drugs.Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.Tipranavir: a protease inhibitor for HIV salvage therapy.Tipranavir: a new option for the treatment of drug-resistant HIV infection.Facile N-arylation of amines and sulfonamides and o-arylation of phenols and arenecarboxylic acids Testing the substrate-envelope hypothesis with designed pairs of compounds.5‑bromo‑3‑(3‑hydroxyprop‑1‑ynyl)‑2H‑pyran‑2‑one induces apoptosis in T24 human bladder cancer cells through mitochondria-dependent signaling pathways.Looking at the proteases from a simple perspective.Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.Tipranavir in the protease inhibitors arena.Human Immunodeficiency Virus Gag and protease: partners in resistance.Process Chemistry in Antiviral Research.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses.Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.

P2860

Q26747290-CB87B34B-B922-4E9D-8AE3-D9E84AF8187E Q27646453-5B972EDC-835D-4101-9ACF-29F84DDD8E4E Q27647177-EE8AEFAB-E9B2-4648-9359-C528CF1E80BF Q27650325-4319DFF8-F7F2-496A-92DC-FA317E748003 Q27660267-4121682B-ECFF-4D2E-974F-0DD137CDA387 Q27665164-BC1D586F-6E06-4170-948A-1E0C3FC84DC8 Q27679177-DD25DAAF-3BAB-4669-90DD-EAAAAF9CCFF9 Q33814096-C479215B-7B83-49AC-81D4-629B0B46FF4F Q33906239-A3381861-EFC8-4B96-B30F-0AFDDC0D0AD8 Q33966254-F41762DD-6F24-4F0A-BBC2-828197FA9B5B Q34102058-F70DE05D-044B-439C-A0A1-FDA371487487 Q34187649-32387A41-B9CD-49D8-B7E3-8FCB9EACFA72 Q34228277-E2F4F7F8-0A71-4D08-B14C-E66D0309B0FC Q34601313-C3705AD1-2008-4CB0-B8EA-62B8B4ED0F43 Q34633457-42BEE890-2ECF-4CE1-B171-9EB539521B48 Q34674166-2EBE92FB-72DF-4AEA-8C2A-70A2A901F222 Q34906937-F4473791-E6B5-42AD-8F60-04ADB16FF0E0 Q34944447-910C6DA5-8C53-49AA-A966-7B8233FD08C5 Q35207282-D157B7F4-D4E2-4345-A06B-AAEE606FADBE Q35260370-09C5A6E1-9E59-4389-BC27-FC83D0DA3793 Q35273893-88D6BACC-5CEE-4009-81EE-6EEF52378C59 Q35570956-96175F80-366F-4754-A414-45F98ACDCCC2 Q35935885-DB6E4B6A-90E4-4E3E-9983-39ADEF3C54D4 Q36150601-6DC0B071-9D3A-4504-A37D-727C6346E692 Q36349653-8BC9679F-9969-4290-9BBF-90F2345BD8E7 Q36482890-A3355305-FFB4-4875-AE9E-37CB74FDEEFB Q36513619-6C376331-2BB2-445E-80D2-34F7F0E6F431 Q36916096-4D46ECEA-5B3C-45D0-933B-A3D2E27B6F64 Q37063610-F5F3B59A-5EA1-40BB-8710-D88E9578D689 Q37323254-C59980E1-A8E2-482A-B86B-DC7FF96C8CE2 Q37707686-6FCD8E71-5CC4-4AA8-8817-D00DCA557DF8 Q37848282-05A45B38-9DBA-4D7E-AC09-2C34AE1DF488 Q37909409-8C970AD4-1B5E-4889-8DBD-7E9A1606AA01 Q37963591-BD7012BD-DCFF-483D-A579-23FC6045EDF9 Q38032330-5BC7C835-3F9E-44C4-8C71-2B3A602EA6EF Q38997200-B8249A1A-7374-407C-ADCC-4541C244721B Q40055204-5AF34C78-7537-4C34-AED7-7DBEC8E091CE Q42003165-BC6620CB-5823-4B0A-9E70-2E65B5CACD9D Q45245263-B22A286B-E7D7-4554-9BA8-063644B51269 Q46990276-72B7F14B-45E6-4C60-A788-E144F79D3EB2

P2860

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

http://www.wikidata.org/entity/Q30040372

description

1998 nî lūn-bûn

@nan

1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇

@ast

Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇

@en

type

label

Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇

@ast

Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇

@en

prefLabel

Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇

@ast

Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇

@en

P1433

Q30040372-FD848B38-61A4-4605-BE24-19B51BC27173

P1476

Q30040372-AE25E6BB-2926-4DCD-80B6-87067AF32D32

P2093

Q30040372-046D3787-26D2-4B6D-A201-7658EEE60400

Q30040372-1F07035F-0B32-45FF-8357-5F1253F24063

Q30040372-23D1684C-6409-44CA-9923-FFC2AC141531

Q30040372-2A5A2EEA-D7FB-40CD-9553-4FF345F22818

Q30040372-3937C615-EE99-495D-BB4A-825D2A92FE9B

Q30040372-424D6AFF-8172-46EB-8B2C-E04A8ECDB9B5

Q30040372-7A0DB0A6-D775-4B65-8420-093DF67FA068

Q30040372-9B67EB9F-7780-40B6-9058-E1A204BE8783

Q30040372-9C2E45A4-1962-4E24-B60D-F5B829E442E5

Q30040372-A1DADAD1-99B5-4E5B-B476-FE7C735210AA

P304

Q30040372-8294724A-FB63-49B6-B7D8-E24FD96A0EEC

P31

Q30040372-3D41F176-27F1-4E14-812C-E619D90C1954

P3181

Q30040372-44BF6C8C-D286-418A-BD40-3D5089DB30B2

P356

Q30040372-C5D242C2-E946-4A34-9292-E68FC1AC5DD7

P407

Q30040372-63ECCA95-67F1-40C6-B073-E43C6A1E4571

P433

Q30040372-2D6E1E16-144F-478B-8678-78FDBFBD8058

P478

Q30040372-666872F8-8005-4517-B967-AE82C6A8837E

P577

Q30040372-81551447-D16D-4031-9785-9A3C3DB61BE9

P698

Q30040372-399BAF28-A333-4DD0-AE6C-5DE723F341C9

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Tipranavir (PNU-140690): A Po ...... xy-2-pyrone Sulfonamide Class∇

@en

P2093

Eric P. Seest

http://www.w3.org/2001/XMLSchema#string

Harvey I. Skulnick

http://www.w3.org/2001/XMLSchema#string

Janet C. Lynn

http://www.w3.org/2001/XMLSchema#string

Joseph W. Strohbach

http://www.w3.org/2001/XMLSchema#string

Keith D. Watenpaugh

http://www.w3.org/2001/XMLSchema#string

Kong-Teck Chong

http://www.w3.org/2001/XMLSchema#string

Lester A. Dolak

http://www.w3.org/2001/XMLSchema#string

Miao-Miao Horng

http://www.w3.org/2001/XMLSchema#string

Michael J. Bohanon

http://www.w3.org/2001/XMLSchema#string

Musiri N. Janakiraman

http://www.w3.org/2001/XMLSchema#string

P304

3467-3476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5057148

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM9802158

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

1998-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9719600

http://www.w3.org/2001/XMLSchema#string